<code id='65BE779EAC'></code><style id='65BE779EAC'></style>
    • <acronym id='65BE779EAC'></acronym>
      <center id='65BE779EAC'><center id='65BE779EAC'><tfoot id='65BE779EAC'></tfoot></center><abbr id='65BE779EAC'><dir id='65BE779EAC'><tfoot id='65BE779EAC'></tfoot><noframes id='65BE779EAC'>

    • <optgroup id='65BE779EAC'><strike id='65BE779EAC'><sup id='65BE779EAC'></sup></strike><code id='65BE779EAC'></code></optgroup>
        1. <b id='65BE779EAC'><label id='65BE779EAC'><select id='65BE779EAC'><dt id='65BE779EAC'><span id='65BE779EAC'></span></dt></select></label></b><u id='65BE779EAC'></u>
          <i id='65BE779EAC'><strike id='65BE779EAC'><tt id='65BE779EAC'><pre id='65BE779EAC'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive